MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 19, 2026Sponsor estimate | NCT05597306Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerrence J Bradley, MD · Acute Myeloid Leukemia | MRKCollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 19, 2026Sponsor estimatePhase 1NCT05597306Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerrence J Bradley, MD · Acute Myeloid LeukemiaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT01731353FungiScope - A Global Emerging Fungal Infection RegistryUniversity of Cologne · Invasive Fungal Disease
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05182164Combination of Pembrolizumab and Cabozantinib in Patients With Advanced SarcomasInstitut Bergonié · Soft Tissue Sarcoma AdultRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05784688Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsTiumBio Co., Ltd. · Solid TumorRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05925491Pembrolizumab in Locally Advanced Sinonasal CarcinomaIstituti Clinici Scientifici Maugeri SpA · Sinonasal Undifferentiated CarcinomaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05956041Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasUniversity of Michigan Rogel Cancer Center · Cutaneous T Cell LymphomaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT05491226Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationStephen Shiao · TNBC - Triple-Negative Breast CancerRecruitingMRKCollaboratorINCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2026Sponsor estimatePhase 1/Phase 2NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLDana-Farber Cancer Institute · Primary Central Nervous System LymphomaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 2NCT04879329A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Seagen, a wholly owned subsidiary of Pfizer · Urothelial CarcinomaRecruitingPFELeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2NCT03684278Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)University of Liverpool · Acute PancreatitisRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1/Phase 2NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PMV Pharmaceuticals, Inc · Advanced Solid TumorRecruitingPMVPLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1/Phase 2NCT05669430A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesGV20 Therapeutics · Solid Tumor, AdultRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimatePhase 2NCT05756569Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyEmory University · Bladder Squamous Cell CarcinomaRecruitingPFECollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT05706779Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerFederation Francophone de Cancerologie Digestive · Colorectal CancerRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT06475235Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLDana-Farber Cancer Institute · LymphomaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT03804944Converting HR+ Breast Cancer Into an Individualized VaccineWeill Medical College of Cornell University · Breast CancerRecruitingMRKCollaboratorCLDXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04443088An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsShenzhen Ionova Life Sciences Co., Ltd. · CancerRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05180097Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaCanadian Cancer Trials Group · Hodgkin LymphomaRecruitingMRKCollaboratorPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1/Phase 2NCT05491083Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast CancerNational University Hospital, Singapore · Advanced Solid TumorRecruitingADAGCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05496036Neoadjuvant PD-1 Blockade in Resectable Merkel Cell CarcinomaAbramson Cancer Center at Penn Medicine · Merkel Cell CarcinomaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06732843Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells...ART Fertility Clinics LLC · OVARIAN STIMULATIONRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT07300085A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Healthy ParticipantsRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT05188508Pembrolizumab, Olaparib, and Temozolomide for People With GliomaMemorial Sloan Kettering Cancer Center · Glioma | MRKCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
| Jan 1, 2027Sponsor estimate | NCT05775471Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract...Jonsson Comprehensive Cancer Center · Renal Pelvis and Ureter Urothelial Carcinoma | PFECollaboratorMRKCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 2NCT05188508Pembrolizumab, Olaparib, and Temozolomide for People With GliomaMemorial Sloan Kettering Cancer Center · GliomaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT05775471Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract...Jonsson Comprehensive Cancer Center · Renal Pelvis and Ureter Urothelial CarcinomaRecruitingPFECollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.